argenx SE (ARGX)
NASDAQ: ARGX
· Real-Time Price · USD
581.31
5.07 (0.88%)
At close: May 29, 2025, 3:59 PM
580.95
-0.06%
After-hours: May 29, 2025, 04:04 PM EDT
0.88% (1D)
| Bid | 561.17 |
| Market Cap | 35.49B |
| Revenue (ttm) | 2.15B |
| Net Income (ttm) | 805.17M |
| EPS (ttm) | 16.41 |
| PE Ratio (ttm) | 35.42 |
| Forward PE | 28.96 |
| Analyst | Buy |
| Ask | 599 |
| Volume | 154,413 |
| Avg. Volume (20D) | 416,939 |
| Open | 577.01 |
| Previous Close | 576.24 |
| Day's Range | 575.01 - 584.27 |
| 52-Week Range | 359.37 - 678.21 |
| Beta | 0.17 |
About ARGX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ARGX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ARGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-8.64%
Argenx shares are trading lower. The company repor...
Unlock content with
Pro Subscription
6 months ago
+3.01%
Argenx shares are trading higher after the company announced the decision to continue development of efgartigimod subcutaneous in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies.
